CA2375854A1 - Nouveau complexe vecteur liposomal et son utilisation en therapie genique - Google Patents

Nouveau complexe vecteur liposomal et son utilisation en therapie genique Download PDF

Info

Publication number
CA2375854A1
CA2375854A1 CA002375854A CA2375854A CA2375854A1 CA 2375854 A1 CA2375854 A1 CA 2375854A1 CA 002375854 A CA002375854 A CA 002375854A CA 2375854 A CA2375854 A CA 2375854A CA 2375854 A1 CA2375854 A1 CA 2375854A1
Authority
CA
Canada
Prior art keywords
complex
component
liposomal vector
vector complex
liposomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002375854A
Other languages
English (en)
Inventor
Sabine Brusselbach
Kristina Muller
Alfred Fahr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectron Therapeutics AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2375854A1 publication Critical patent/CA2375854A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un nouveau complexe vecteur liposomal comprenant les composants suivants : a) une séquence d'acide nucléique de longueur indifférente; b) un support cationique qui condense le composant a) et est lysosomolytique et/ou lysosomotrope; c) des lipides et phospholipides formant un liposome; d) éventuellement un ligand possédant un site de liaison pour une cellule cible; et e) éventuellement une substance fusogène qui peut remplacer la fonction lysosomolytique et/ou lysosomotrope du composant b). En présence d'une substance fusogène (e), le support cationique (b) ne doit pas être lysosomolytique et/ou lysosomotrope. Cette invention concerne également la production de ce complexe et son utilisation.
CA002375854A 1999-06-02 2000-05-23 Nouveau complexe vecteur liposomal et son utilisation en therapie genique Abandoned CA2375854A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19925143A DE19925143A1 (de) 1999-06-02 1999-06-02 Neue liposomale Vektorkomplexe und deren Verwendung für die Gentherapie
DE19925143.6 1999-06-02
PCT/EP2000/004678 WO2000074646A2 (fr) 1999-06-02 2000-05-23 Nouveau complexe vecteur liposomal et son utilisation en therapie genique

Publications (1)

Publication Number Publication Date
CA2375854A1 true CA2375854A1 (fr) 2000-12-14

Family

ID=7909923

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002375854A Abandoned CA2375854A1 (fr) 1999-06-02 2000-05-23 Nouveau complexe vecteur liposomal et son utilisation en therapie genique

Country Status (6)

Country Link
EP (1) EP1187929A2 (fr)
JP (1) JP2003501373A (fr)
AU (1) AU4758300A (fr)
CA (1) CA2375854A1 (fr)
DE (1) DE19925143A1 (fr)
WO (1) WO2000074646A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT103865A (pt) * 2007-10-25 2009-05-15 Univ De Coimbra Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
JP2020500020A (ja) 2016-11-14 2020-01-09 ノバルティス アーゲー 融合誘導性タンパク質ｍｉｎｉｏｎに関連する組成物、方法、および治療上の使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
EP0784984B1 (fr) * 1996-01-17 2003-07-02 F. Hoffmann-La Roche Ag Molécules compétentes à la transfection
EP0979311A1 (fr) * 1997-04-30 2000-02-16 Of The University Of Minnesota Regents UTILISATION $i(IN VIVO) D'OLIGONUCLEOBASES RECOMBINAGENES POUR CORRIGER LES LESIONS GENETIQUES DES HEPATOCYTES
CA2327367A1 (fr) * 1998-04-07 1999-10-14 Roche Diagnostics Gmbh Nouveaux composes destines a la transfection d'adn
AU747597B2 (en) * 1998-07-20 2002-05-16 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9387152B2 (en) 2010-06-28 2016-07-12 The General Hospital Corporation Blood substitutes and uses thereof

Also Published As

Publication number Publication date
WO2000074646A3 (fr) 2001-08-09
EP1187929A2 (fr) 2002-03-20
WO2000074646A2 (fr) 2000-12-14
AU4758300A (en) 2000-12-28
JP2003501373A (ja) 2003-01-14
DE19925143A1 (de) 2000-12-07

Similar Documents

Publication Publication Date Title
Harris et al. Tissue-specific gene delivery via nanoparticle coating
McCarthy et al. Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery
CN1863558B (zh) 具有向核内转移能力的聚精氨酸修饰的脂质体
US20210170046A1 (en) Improved lipid-peptide nanocomplex formulation for mrna delivery to cells
US20050163832A1 (en) Intracellular delivery of therapeutic agents
US20030045465A1 (en) Histidine copolymer and methods for using same
US20080171025A1 (en) Highly Branched Hk Peptides as Effective Carriers of Sirna
JP2003528131A (ja) カチオン性リポソーム
US6372720B1 (en) Liposome fusion and delivery vehicle
WO1997000965A2 (fr) Vecteur lipidique servant a l'administration d'acides nucleiques
MX2014004415A (es) Bicapas lipidicas soportadas por nanoparticulas porosas (protecelulas) para suministro dirigido, incluido el suministro transdermico de carga, y los metodos relacionados.
US11793756B2 (en) Anionic nanocomplexes for nucleic acid delivery
WO2013140643A1 (fr) Support pour l'administration intracellulaire d'une protéine fonctionnelle
JP2003507348A (ja) 標的設定人工遺伝子送達
WO2023093596A1 (fr) Vecteur de polypeptide cyclique pour une administration efficace d'un acide nucléique, et ses variants
JP2003514843A (ja) モジュラー標的化リポソーム送達システム
CA2375854A1 (fr) Nouveau complexe vecteur liposomal et son utilisation en therapie genique
Bansal Non-viral vectors for gene delivery
JP2006514924A (ja) 走触性ペプチドを含むリポソーム組成物及びその使用
EP4674431A1 (fr) Nanoparticules lipidiques, composition pharmaceutique et procédé de production de nanoparticules lipidiques
US20230121879A1 (en) Methods for preparing nanoparticle compositions containing histidine-lysine copolymers
US20230233476A1 (en) Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index
US20240033374A1 (en) Nano-structural Protein Degradation Tool, Use, and Preparation Method thereof, and Lipid-based Protein Degradation Tool, Use, and Preparation Method thereof
JP2008031142A (ja) 脂肪組織標的化ペプチド及び該ペプチドを有するリポソーム
Wilson Polymeric Nanoparticle Engineering for Delivery of Nucleic Acids

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued